Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Expands Commercialization Strategy with $375K Financing, Investor Awareness Agreements, and Breakthrough Personalized Radiation Dose Breast CT

• Izotropic Corp. marks a significant milestone in breast imaging with its patent-pending personalized radiation dose feature with the IzoView Breast CT system
• Recently, the company secured a $375,000 non-brokered private placement to help with core operations in addition to engaging new PR partners for improved investor communications
• With projections for global breast imaging expected to hit $8.69 billion by 2030, the company is poised to strategically dominate the market

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a leading medical device firm in the field of breast cancer imaging solutions, is speeding up its efforts towards commercializing its innovations. Izotropic recently made public significant progress in its IzoView Breast CT system, a feature designed to give patients a customized radiation dose ideal for their composition and breast sizes (ibn.fm/N83Cp).

The system calculates personalized dosage for each patient using a patent-pending dosing system that is embedded in a radiation-free optical pre-scan. With this unique innovation, workflow is improved, manual dose selection is eliminated, and patient safety is prioritized. Combined with IzoView’s AI-driven image optimization and contact- and compression-free design, this capability helps ensure that the clinical value proposition of the system is strengthened towards CE mark and FDA pre-market submissions.

These developments are in line with the breast imaging solution market, which is expected to grow to $8.69 billion by 2030 from $5.4 billion in 2024 due to increased incidences of breast cancer, adoption of personalized screen protocols, and expansion of reimbursements. The company’s one-of-a-kind, patient-targeted dosing model places the system at the epicenter.

In addition to the latest technical updates, the company is also consolidating its communications and financial systems. Izotropic recently secured a $375,000 non-brokered private placement, with 1.5 million units valued at $0.25. The proceeds of the money raised are expected to be used for working capital as the company prepared for its U.S. clinical study (ibn.fm/grIMG).

The company has also reached strategic partnerships with Departures Capital Inc. and Evolux Capital, two investor relations and awareness brands focused on boosting digital marketing, communications, and consulting. These strategic moves are targeted at improving the brand’s investment community visibility as it takes more steps towards consolidating its current gains.

Izotropic continues to intensify efforts aligned with its mission to deliver purpose-built breast imaging technologies that improve diagnostic confidence and patient experience. By securing working capital, recording improved imaging capabilities, and enhancing investor confidence, the company is progressing towards commercialization, highlighting its interest in creating value for shareholders and endline users.

For more information, visit the company’s website at www.IzoCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at ibn.fm/IZOZF

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN